Sign in

CIK 0001840233

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

Xilio Therapeutics, Inc.

Sign in to watch
Ticker
XLO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
851623397
Phone
+1 617-833-1027
Business address
828 WINTER STREET, WALTHAM, MA, 02451
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$0
in 0 filings

Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2023-08-16 Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D Grant or award · Stock Option (right to buy) +136,500 136,500
2023-01-01 Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D Grant or award · Stock Option (right to buy) +136,500 136,500
2022-06-15 Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D Grant or award · Stock Option (right to buy) +20,000 20,000
2022-06-15 Huber Martin H. Jr. PRESIDENT AND HEAD OF R&D Grant or award · Stock Option (right to buy) +20,000 20,000
2022-02-22 Huber Martin H. Jr. PRESIDENT OF R&D AND CMO Grant or award · Stock Option (right to buy) +65,000 65,000
2021-10-21 Huber Martin H. Jr. President of R&D and CMO Grant or award · Stock Option (right to buy) +157,058 157,058

Page 1 of 1 · 6 trades